Follow the people · Insider
Daljit Singh Aurora
Daljit Singh Aurora files insider transactions with the SEC as an officer of Neumora Therapeutics (NMRA). We hold 6 disclosed purchases and sales filed since 13 November 2019, 5 of them in the last 90 days.
- Files forNMRA
- Disclosed buys and sells6 in all, 5 in the last 90 days
- Last disclosure21 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 14 February 2024 — 21 August 2026Officer · Neumora Therapeutics (NMRA)90 Form 4 lines · source: SEC Form 4
- Filed 11 November 2019 — 20 February 2020Chief Scientific Affairs Off · Dermira (DERM)16 Form 4 lines · source: SEC Form 4
Everything they disclosed
106 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 67,741 shares of Neumora TherapeuticsSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- exercised options over 67,741 shares of Neumora Therapeutics (a derivative holding)SEC Form 421 August 2026Stock Option (Right to Buy) · traded 20 August 2026 · filed 21 August 2026
- exercised options over 45,026 shares of Neumora Therapeutics (a derivative holding)SEC Form 421 August 2026Stock Option (Right to Buy) · traded 20 August 2026 · filed 21 August 2026
- exercised options over 21,685 shares of Neumora Therapeutics (a derivative holding)SEC Form 421 August 2026Stock Option (Right to Buy) · traded 20 August 2026 · filed 21 August 2026
- was granted 200,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 421 August 2026Stock Option (Right to Buy) · traded 20 August 2026 · filed 21 August 2026
- exercised options over 20,553 shares of Neumora Therapeutics (a derivative holding)SEC Form 421 August 2026Stock Option (Right to Buy) · traded 21 August 2026 · filed 21 August 2026
- exercised options over 21,055 shares of Neumora Therapeutics (a derivative holding)SEC Form 421 August 2026Stock Option (Right to Buy) · traded 21 August 2026 · filed 21 August 2026
- ▼ sold on the open market 67,741 shares of Neumora TherapeuticsSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- exercised options over 21,685 shares of Neumora TherapeuticsSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- exercised options over 45,026 shares of Neumora TherapeuticsSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- ▼ sold on the open market 66,711 shares of Neumora TherapeuticsSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- exercised options over 20,553 shares of Neumora TherapeuticsSEC Form 421 August 2026Common Stock · traded 21 August 2026 · filed 21 August 2026
- ▼ sold on the open market 20,553 shares of Neumora TherapeuticsSEC Form 421 August 2026Common Stock · traded 21 August 2026 · filed 21 August 2026
- exercised options over 21,055 shares of Neumora TherapeuticsSEC Form 421 August 2026Common Stock · traded 21 August 2026 · filed 21 August 2026
- ▼ sold on the open market 21,055 shares of Neumora TherapeuticsSEC Form 421 August 2026Common Stock · traded 21 August 2026 · filed 21 August 2026
- exercised options over 40,890 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- exercised options over 34,162 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 18 August 2026 · filed 19 August 2026
- ▼ sold on the open market 34,162 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 18 August 2026 · filed 19 August 2026
- exercised options over 34,987 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 18 August 2026 · filed 19 August 2026
- ▼ sold on the open market 34,987 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 18 August 2026 · filed 19 August 2026
- exercised options over 13,268 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- exercised options over 17,732 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- ▼ sold on the open market 31,000 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- exercised options over 30,918 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- ▼ sold on the open market 30,918 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- exercised options over 40,890 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 17 August 2026 · filed 19 August 2026
- exercised options over 15,355 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- exercised options over 15,355 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 17 August 2026 · filed 19 August 2026
- exercised options over 1,424 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 17 August 2026 · filed 19 August 2026
- exercised options over 1 share of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 17 August 2026 · filed 19 August 2026
- exercised options over 25,279 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 17 August 2026 · filed 19 August 2026
- exercised options over 29,737 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 17 August 2026 · filed 19 August 2026
- exercised options over 34,162 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 18 August 2026 · filed 19 August 2026
- exercised options over 34,987 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 18 August 2026 · filed 19 August 2026
- exercised options over 13,268 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 19 August 2026 · filed 19 August 2026
- exercised options over 17,732 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 19 August 2026 · filed 19 August 2026
- exercised options over 30,918 shares of Neumora Therapeutics (a derivative holding)SEC Form 419 August 2026Stock Option (Right to Buy) · traded 19 August 2026 · filed 19 August 2026
- exercised options over 1,424 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- exercised options over 1 share of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 57,670 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 34,020 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- exercised options over 25,279 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- exercised options over 29,737 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 55,016 shares of Neumora TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 6,165 shares of Neumora TherapeuticsSEC Form 419 February 2026Common Stock · traded 17 February 2026 · filed 19 February 2026
- ▼ sold on the open market 6,165 shares of Neumora TherapeuticsSEC Form 419 February 2026Common Stock · traded 17 February 2026 · filed 19 February 2026
- was granted 750,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 49 January 2026Stock Option (Right to Buy) · traded 8 January 2026 · filed 9 January 2026
- was granted 750,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 49 January 2026Stock Option (Right to Buy) · traded 8 January 2026 · filed 9 January 2026
- ▼ sold on the open market 114,703 shares of Neumora TherapeuticsSEC Form 413 November 2025Common Stock · traded 11 November 2025 · filed 13 November 2025
- returned to the issuer 40,890 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- returned to the issuer 137,538 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- returned to the issuer 207,901 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- returned to the issuer 136,210 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- returned to the issuer 72,221 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- returned to the issuer 29,737 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- returned to the issuer 195,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- returned to the issuer 1,000,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- was granted 40,890 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- was granted 137,538 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- was granted 207,901 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- was granted 136,210 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- was granted 72,221 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- was granted 29,737 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- was granted 195,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- was granted 1,000,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 430 May 2025Stock Option (Right to Buy) · traded 28 May 2025 · filed 30 May 2025
- ▼ sold on the open market 8,565 shares of Neumora TherapeuticsSEC Form 420 February 2025Common Stock · traded 18 February 2025 · filed 20 February 2025
- was granted 1,000,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- returned to the issuer 40,890 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- returned to the issuer 137,538 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- returned to the issuer 207,901 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- returned to the issuer 136,210 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- returned to the issuer 72,221 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- returned to the issuer 29,737 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- returned to the issuer 195,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- was granted 40,890 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- was granted 137,538 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- was granted 207,901 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- was granted 136,210 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- was granted 72,221 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- was granted 29,737 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- was granted 195,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 418 February 2025Stock Option (Right to Buy) · traded 13 February 2025 · filed 18 February 2025
- gave away 137,538 shares of Neumora Therapeutics (a derivative holding)SEC Form 413 September 2024Stock Option (Right to Buy) · traded 12 September 2024 · filed 13 September 2024
- gave away 137,538 shares of Neumora Therapeutics (a derivative holding)SEC Form 413 September 2024Stock Option (Right to Buy) · traded 12 September 2024 · filed 13 September 2024
- gave away 136,210 shares of Neumora Therapeutics (a derivative holding)SEC Form 413 September 2024Stock Option (Right to Buy) · traded 12 September 2024 · filed 13 September 2024
- gave away 136,210 shares of Neumora Therapeutics (a derivative holding)SEC Form 413 September 2024Stock Option (Right to Buy) · traded 12 September 2024 · filed 13 September 2024
- gave away 29,737 shares of Neumora Therapeutics (a derivative holding)SEC Form 413 September 2024Stock Option (Right to Buy) · traded 12 September 2024 · filed 13 September 2024
- gave away 29,737 shares of Neumora Therapeutics (a derivative holding)SEC Form 413 September 2024Stock Option (Right to Buy) · traded 12 September 2024 · filed 13 September 2024
- gave away 114,703 shares of Neumora TherapeuticsSEC Form 424 April 2024Common Stock · traded 22 April 2024 · filed 24 April 2024
- was granted 195,000 shares of Neumora Therapeutics (a derivative holding)SEC Form 416 February 2024Stock Option (Right to Buy) · traded 14 February 2024 · filed 16 February 2024
- was granted 97,500 shares of Neumora TherapeuticsSEC Form 416 February 2024Common Stock · traded 14 February 2024 · filed 16 February 2024
- returned to the issuer 67,500 shares of Dermira (a derivative holding)SEC Form 424 February 2020Employee Stock Options (Right to buy) · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 11,500 shares of Dermira (a derivative holding)SEC Form 424 February 2020Employee Stock Options (Right to buy) · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 28,130 shares of Dermira (a derivative holding)SEC Form 424 February 2020Employee Stock Options (Right to buy) · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 7,040 shares of Dermira (a derivative holding)SEC Form 424 February 2020Employee Stock Options (Right to buy) · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 50,000 shares of Dermira (a derivative holding)SEC Form 424 February 2020Employee Stock Options (Right to buy) · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 28,000 shares of Dermira (a derivative holding)SEC Form 424 February 2020Employee Stock Options (Right to buy) · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 6,250 shares of Dermira (a derivative holding)SEC Form 424 February 2020Restricted Stock Unit · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 574 shares of Dermira (a derivative holding)SEC Form 424 February 2020Restricted Stock Unit · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 2,814 shares of Dermira (a derivative holding)SEC Form 424 February 2020Restricted Stock Unit · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 708 shares of Dermira (a derivative holding)SEC Form 424 February 2020Restricted Stock Unit · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 22,500 shares of Dermira (a derivative holding)SEC Form 424 February 2020Restricted Stock Unit · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 10,000 shares of Dermira (a derivative holding)SEC Form 424 February 2020Restricted Stock Unit · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 6,000 shares of Dermira (a derivative holding)SEC Form 424 February 2020Restricted Stock Unit · traded 20 February 2020 · filed 24 February 2020
- returned to the issuer 30,089 shares of DermiraSEC Form 424 February 2020Common Stock · traded 20 February 2020 · filed 24 February 2020
- was granted 6,000 shares of Dermira (a derivative holding)SEC Form 413 November 2019Restricted Stock Unit · traded 11 November 2019 · filed 13 November 2019
- was granted 28,000 shares of Dermira (a derivative holding)SEC Form 413 November 2019Stock Options (Right to buy) · traded 11 November 2019 · filed 13 November 2019
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.